Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 713 clinical trials
Featured trial
A Phase 2, Single-Arm, Open-Label Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy by Immune Effector Cell Therapy

The purpose of this study is to assess the safety and efficacy of oral administration of itacitinib once daily for the prevention of cytokine release syndrome (CRS) in male or female participants aged 12 years or older and who are planning to receive tisagenlecleucel or axicabtagene ciloleucel immune effector cell …

cancer
hematologic cancer
  • 126 views
  • 10 May, 2022
  • 10 locations
Featured trial
Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia

Background: Severe aplastic anemia is a rare and serious blood disorder. It happens when the immune system starts to attack the bone marrow cells. This causes the bone marrow to stop making red blood cells, platelets, and white blood cells. Standard treatment for this disease is horse-ATG and cyclosporine, which …

myelodysplastic syndrome (mds)
anemia studies
anemia
aplastic anemia
myelodysplastic syndromes
  • 172 views
  • 22 Dec, 2020
  • 1 location
EFFECTIVENESS SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19

This study is clinical trial (intervention study with external comparison group) to test vaccination with reduced dose (half dose) of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, including all adults aged 18 to 49 years from Viana city - Esprito Santo (ES)/Brazil, on the …

Accepts healthy volunteers
  • 6 views
  • 06 Oct, 2021
  • 1 location
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis (AFFINITY)

The purpose of this study is to evaluate the efficacy of guselkumab plus golimumab combination treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) to a prior anti-tumor necrosis factor-alpha (anti-TNF-alpha) therapy by assessing clinical response compared with guselkumab monotherapy.

psoriasis
tumor necrosis factor
rheumatoid nodules
golimumab
arthritis mutilans
  • 5 views
  • 02 May, 2022
  • 27 locations
COVID-19 VACCINE SAFETY AND EFFECTIVENESS

A longitudinal open-label study will include health professionals and patients with immune-mediated inflammatory diseases (IMID) who will receive the ChAdOx1 nCoV-19 vaccine (AZD1222), in a standard 3-dose schedule with an interval of 12 weeks (first-second dose) and 24 weeks (second-thrid dose), in the vaccination campaign against SARS-CoV-2 to assess the …

Accepts healthy volunteers
  • 0 views
  • 02 Dec, 2021
  • 1 location
Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE (ACTIV-4A)

This is a randomized, open label, adaptive platform trial to compare the effectiveness of antithrombotic and additional strategies for prevention of adverse outcomes in COVID-19 positive inpatients

  • 243 views
  • 24 Mar, 2022
  • 98 locations
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)

This study will characterize the safety and tolerability and identify the recommended Phase 2 dose (RP2D) of subcutaneous (SC) ALKS 4230 as monotherapy and in combination with pembrolizumab.

  • 39 views
  • 22 Mar, 2022
  • 37 locations
The Influence by Dietary Human Milk Oligosaccharide in Low Birth Weight Infants

This study aims to investigate the concentration of various growth factors and cytokines in blood, and to examine the gut microbiota of low birth weight infants fed with formulas with or without

  • 0 views
  • 24 Mar, 2022
  • 1 location
Randomized Trial of Curcumin to Reduce Mucositis in Autologous Transplant Setting

have been accepted as a standard to prevent and treat mucositis in the transplant setting. Post transplant upto 80% of patients suffer from a severe mucositis. Proinflammatory cytokines play a major

  • 0 views
  • 30 May, 2021
  • 1 location
Adding Colchicine to Tocilizumab in Patients With Severe COVID-19 Pneumonia.

Colchicine acts upstream in the cytokines cascade by inhibiting the NLRP3 inflammasome while IL-6 receptor antagonists (tocilizumab) block the end result of the cytokines cascade. Hence, adding

  • 0 views
  • 10 Dec, 2021
  • 1 location